# MOTS-c peptide: Mitochondrial-Derived Signal Studied for Metabolism and Aging > MOTS-c peptide is a 16-amino-acid mitochondrial-derived peptide that activates AMPK and is studied for glucose handling, exercise-mimetic capacity, and aging. A depth-graded literature digest, cited to source. A depth-gauged digest of what the literature establishes near the surface — and how deep the honest gaps run. Every quantitative claim is graded by evidence depth and cited to source. ## The short version The **MOTS-c peptide** is a tiny molecule your own mitochondria make. Mitochondria are the parts of a cell that produce energy, and MOTS-c is a 16-amino-acid peptide (a very short protein) encoded inside one of the mitochondrial genes. In mice and in cells, it switches on AMPK — the enzyme a cell uses as its low-fuel sensor — which improves how the body handles blood sugar. Most of what we know comes from animal and cell studies. The human evidence is thin and observational: it tells us MOTS-c *associates* with metabolic and heart-risk markers, not yet that giving it to people changes outcomes. ## What the MOTS-c peptide is, near the surface and at depth MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA type-c) is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR, encoded by a short open reading frame within the mitochondrial 12S ribosomal RNA gene (MT-RNR1) [4]. It is endogenous — your cells already make it — and it is detectable in human plasma and skeletal muscle, where its level rises with exercise and shifts with age and metabolic state [2]. The peptide's best-characterized action is inhibition of the folate cycle (the one-carbon reactions that build the purine bases of DNA and RNA), which raises an intermediate called AICAR and activates AMPK (AMP-activated protein kinase, the cell's low-fuel sensor) [1]. That single mechanism improves glucose handling, primarily in skeletal muscle. Under metabolic stress MOTS-c does something rare for a mitochondrial peptide: it translocates from the mitochondrion to the nucleus and changes which genes are switched on [3]. This site grades each finding by the depth at which its certainty sits. Human signal — observational, biomarker-level — sits in the lit surface band. Animal and cell findings sit in the broad preclinical mid-water. The honest gaps — no completed human efficacy trial, no validated human half-life — sit in the abyss, in plain view rather than papered over. ## What Is MOTS-c? ### What Is MOTS-c? MOTS-c is a mitochondrial-derived peptide (MDP) — a bioactive peptide encoded by the mitochondrial genome rather than by nuclear DNA, in the same family as humanin and the SHLPs [9]. It is 16 amino acids long, has a molecular weight of 2174.61 Da, and carries CAS number 1627580-64-6 [4]. The founding 2015 study identified it, mapped its AMPK mechanism, and named skeletal muscle as its primary target organ [1]. A 2023 review in the *Journal of Translational Medicine* is the modern reference frame, consolidating its encoding within MT-RNR1, its metabolic and stress-adaptive roles, and its place in aging biology [4]. ### What does the MOTS-c peptide do? MOTS-c inhibits the folate cycle to activate AMPK, which improves glucose handling in skeletal muscle, and it can translocate to the nucleus to regulate stress-response genes [1][3]. A 2024 study added a direct molecular target — MOTS-c binds and activates casein kinase 2 (CK2), a constitutively active enzyme, with tissue-specific effects: activation in muscle, suppression in fat [10]. ## What the Research Says About MOTS-c Benefits The research-stage effects attributed to the MOTS-c peptide cluster in metabolism, physical capacity, and stress resilience — and every one of them, to date, rests on animals or cells rather than human trials. In the founding work, MOTS-c prevented diet-induced obesity and both age-dependent and high-fat-diet-induced insulin resistance in mice [1]. Insulin resistance is the state in which cells stop responding well to insulin's signal to take up glucose; preventing it is the core metabolic claim. In aged mice, exogenous MOTS-c at 15 mg/kg significantly increased treadmill running capacity (P=0.000002), grip strength, and gait, which is why it is studied as an exercise mimetic — a compound that reproduces some adaptations of physical exercise [2]. The same study showed that exercise itself induces the body's own MOTS-c, tying the peptide to physical decline with age. At the molecular level, MOTS-c has been shown to reduce myostatin (a protein that limits muscle growth) and muscle-atrophy signaling, and to aid plasma-membrane repair via the protein TRIM72 (MG53) [10]. These are mechanisms of muscle *preservation*, not hypertrophy. None of these benefits is confirmed in a human efficacy trial. ### What are the potential benefits of MOTS-c? Research-stage benefits seen in animals and cells include improved insulin sensitivity, enhanced physical capacity, adipose thermogenesis (heat-producing fat activation), and muscle and islet protection [1][2][7]. None has been confirmed in human trials; the human evidence remains observational. ## Where the human evidence actually sits The deepest-running human data is observational, and it is worth stating precisely. Circulating MOTS-c is lower in obese male children and adolescents and is inversely associated with insulin resistance [5], and a separate pediatric study linked lower serum MOTS-c to measures of vascular endothelial function [6]. In adults, the strongest human-association data comes from a 2024 prospective multicenter cohort of 94 chronic hemodialysis patients, where circulating MOTS-c was independently associated with a composite of all-cause mortality and non-fatal cardiovascular events (Cox HR 1.004, p=0.05) and improved a risk model's discrimination (ROC AUC 0.727 to 0.743) [11]. These are biomarker associations — they describe MOTS-c that the body produced, not MOTS-c given as a treatment. The gap between that surface signal and the broad preclinical layer beneath it is the honest center of this digest. For the cardiometabolic evidence in full, including [MOTS-c and type 2 diabetes](/cardiometabolic-research), see the [MOTS-c cardiometabolic research](/cardiometabolic-research) page; the full [MOTS-c research findings](/research) sit on the research page, and for the regulatory picture — including whether [is MOTS-c legal](/legal-status) — see [MOTS-c legal status and 503A access](/legal-status). --- A depth-gauged reading of the MOTS-c mitochondrial-peptide record — the human signal logged near the surface, the preclinical findings in the mid-water, and the honest gaps left visible in the abyss, with no clinic behind the gauge and nothing here stocked, priced, or sold.